
News|Articles|December 19, 2023
- MHE December 2023
- Volume 33
- Issue 12
State of the Industry: Key Issues, Technology Impact, Presidential Campaign Focus, and Challenges Ahead in 2024
We conducted our annual State of the Industry survey in the early part of November 2023. The survey had 432 respondents, of whom 56% self-reported working for a payer organization (pharmacy benefit manager, insurer or self-insured employer), 34% for a provider organization and the remainder for government or an unspecified “other” category.
Advertisement
Articles in this issue
about 2 years ago
The Best Hope for Eradicating HCVabout 2 years ago
Biosimilars are Ascendantabout 4 years ago
ICER: More Transparency of Drug Coverage Policies NeededNewsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The FDA proposes ditching comparative efficacy studies for biosimilars
2
How new psoriasis, alopecia and atopic dermatitis therapies stood out at Fall Clinical Derm 2025
3
UC Davis develops new drug for bladder cancer patients
4
Phase 3 trial launches for novel antibody targeting integrin beta-6 in advanced lung cancer
5




















































